Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitophagy is the selective degradation of damaged or redundant mitochondria via the autophagy-lysosomal pathway, serving as a critical mechanism for mitochondrial quality control and cellular homeostasis [1, 2]. The PINK1-Parkin-dependent pathway is the most extensively studied, involving the accumulation of PTEN-induced kinase 1 (PINK1) on the outer mitochondrial membrane of depolarized mitochondria, which subsequently recruits and activates the E3 ubiquitin ligase Parkin [2, 3]. Parkin then ubiquitinates various mitochondrial proteins, signaling for autophagosomal engulfment. Conversely, PINK1-Parkin-independent mitophagy is mediated by specific receptors such as BNIP3, NIX, and FUNDC1, which contain LC3-interacting regions (LIR) to directly recruit autophagosomes to the mitochondria [3, 4]. Impairment of these pathways is a hallmark of neurodegenerative diseases, most notably Parkinson's disease, where mutations in PINK1 and PRKN (Parkin) lead to the accumulation of dysfunctional mitochondria and neuronal death [5]. Therapeutic interventions targeting this pathway include the development of PINK1 activators, Parkin activators, and inhibitors of USP30, a deubiquitinating enzyme that opposes Parkin-mediated mitophagy [6, 7].
Activation of PINK1 or Parkin, or inhibition of USP30 to promote the clearance of damaged mitochondria.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitophagy pathway (PINK1-Parkin-dependent and independent) (Mitophagy).